Cambridge Healthtech Institute’s Inaugural

Next-Generation Immunotherapies

Engineering Next-Gen Biotherapeutics in Immuno-Oncology

August 8-9, 2019



Cambridge Healthtech Institute's Inaugural Next-Generation Immunotherapies conference will feature presentations on the latest immunotherapy technologies from emerging companies. Learn about engineering the next-generation immunotherapies coming down the pipeline, including bi-specific and multi-specific antibody constructs, fully recombinant antibody prodrugs, innovative multivalent therapeutics, immunotherapeutic fusion proteins, antibody-drug conjugates, small molecules, engineered cells, and other innovative approaches.

SMALL MOLECULES AND ADCs

Modulation of Immune Metabolism for Effective Anti-Tumor Response
Chan Whiting, PhD, Senior Vice President, R&D, Tempest Therapeutics

NBE-002, a Site-Specifically Conjugated, ROR1-Specific Anthracycline-ADC with Potent Immune-Stimulatory Functions
Roger R. Beerli, PhD, CSO, NBE-Therapeutics Ltd.

NEXT-GEN PROTEIN ENGINEERING

CUE-101, a Novel Fc Fusion Protein for Selective Targeting and Expansion of Anti-Tumor T Cells for Treatment of HPV-Driven Malignancies
Saso Cemerski, PhD, Senior Director, Translational Immunology, Cue Biopharma

CYTOKINES: TARGETS AND THERAPEUTICS

Development of TNF Superfamily Agonists
Andreas Raue, Director, Research, Merrimack Pharmaceuticals, Inc.

Cytokine Engineering for Immuno-Oncology Using Polymer Conjugation
Steve Doberstein, PhD, CSO & Senior Vice President, Research, Nektar Therapeutics

The TNFR2 Immuno-Oncology Target
Denise Faustman, MD, PhD, Associate Professor & Director, Immunobiology Lab, Massachusetts General Hospital, Harvard Medical School

NEXT-GENERATION CELLULAR IMMUNOTHERAPIES: DENDRITIC CELL VACCINES

Personal Dendritic Cell Anti-Cancer Vaccines: Autologous Dendritic Cells Loaded with Tumor Antigens from Autologous Tumor Initiating Cells
Robert O. Dillman, MD, CMO, AIVITA Biomedical

Autologous Dendritic Cell Vaccines for Prostate and HER2-Expressing Cancers
Jay A. Berzofsky, MD, PhD, Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute

PLENARY PANEL DISCUSSION: PARTNERING AND LICENSING IN IMMUNO-ONCOLOGY

Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will discuss their areas of interest for in-licensing novel therapeutics, devices and diagnostics and what they look for in a partner or investment.

Panelists: Michael Woo, MBA, Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

Kathryn McCabe, PhD, Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company

Scott M. DeWire, PhD, Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag



Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com